Search Results for: CREB3L1

197 interactions involving CREB3L1 - cAMP responsive element binding protein 3 like 1 found:

Sort by: Symbol Number of Pathways Number of Drugs Number of Diseases
Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
BRICD5 BRICHOS domain containing 5
C11orf24 chromosome 11 open reading frame 24
C4orf3 chromosome 4 open reading frame 3
C5 complement C5
  • Terminal pathway of complement
  • Activation of C3 and C5
  • Peptide ligand-binding receptors
  • G alpha (i) signalling events
  • Regulation of Complement cascade
  • Human immunoglobulin G
  • Eculizumab
  • Zinc
  • Copper
  • Ravulizumab
  • Zinc acetate
  • Zinc chloride
  • Zinc sulfate, unspecified form
  • Late complement pathway defects, including the following seven diseases: C5 deficiency; C6 deficiency; C7 deficiency; C8 alpha-chain deficiency; C8 beta-chain deficiency; C8 gamma-chain deficiency; C9 deficiency
CCL4L2 C-C motif chemokine ligand 4 like 2
  • G alpha (i) signalling events
CD53 CD53 molecule
  • Neutrophil degranulation
CD72 CD72 molecule
  • Other semaphorin interactions
CD99L2 CD99 molecule like 2
  • Cell surface interactions at the vascular wall
CFHR5 complement factor H related 5
  • Regulation of Complement cascade
CIAO2A cytosolic iron-sulfur assembly component 2A
CLN6 CLN6 transmembrane ER protein
  • Neuronal ceroid lipofuscinosis, including: Infantile Neuronal Ceroid Lipofuscinosis (INCL)/ Santavuori-Haltia Disease (CLN1); Late-Infantile Neuronal Ceroid Lipofuscinosis (LINCL)/ Jansky-Bielschowsky Disease (CLN2); Juvenile Neuronal Ceroid Lipofuscinosis (JNCL)/Batten Disease/ Spielmeyer-Vogt Disease (CLN3); Adult Neuronal Ceroid Lipofuscinosis (ANCL)/ Kufs Disease (CLN4); LINCL variant (CLN5, CLN6, CLN7, CLN8); Batten Disease variant (CLN9); Congenital NCL (CLN10)
  • Progressive myoclonic epilepsy (PME), including: Lafora disease (LBD); Unverricht-Lundborg disease (ULD); Neuronal ceroid lipofuscinoses (NCL); Type I sialidosis; Action myoclonus-renal failure syndrome (AMRF); Type III Gaucher disease (GD)
CMTM3 CKLF like MARVEL transmembrane domain containing 3
CMTM7 CKLF like MARVEL transmembrane domain containing 7
CNIH2 cornichon family AMPA receptor auxiliary protein 2
  • COPII-mediated vesicle transport
  • Cargo concentration in the ER
COL8A2 collagen type VIII alpha 2 chain
  • Collagen degradation
  • Collagen degradation
  • Collagen biosynthesis and modifying enzymes
  • Assembly of collagen fibrils and other multimeric structures
  • Integrin cell surface interactions
  • Collagen chain trimerization
  • Posterior polymorphous corneal dystrophy (PPCD)
  • Fuchs corneal dystrophy (FECD); Fuchs endothelial corneal dystrophy
COMT catechol-O-methyltransferase
  • Methylation
  • Enzymatic degradation of dopamine by COMT
  • Enzymatic degradation of Dopamine by monoamine oxidase
  • Potential therapeutics for SARS
  • Ademetionine
  • Tolcapone
  • Entacapone
  • 3,5-Dinitrocatechol
  • 2-Methoxyestradiol
  • BIA
  • N-[(E)-3-[(2R,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]prop-2-enyl]-2,3-dihydroxy-5-nitrobenzamide
  • Nialamide
  • (3,4-DIHYDROXY-2-NITROPHENYL)(PHENYL)METHANONE
  • 7,8-dihydroxy-4-phenyl-2H-chromen-2-one
  • Opicapone
COX20 cytochrome c oxidase assembly factor COX20
  • TP53 Regulates Metabolic Genes
  • Respiratory electron transport
CREB3 cAMP responsive element binding protein 3
  • CREB3 factors activate genes
  • CREB3 factors activate genes
CREB3L3 cAMP responsive element binding protein 3 like 3
  • CREB3 factors activate genes
  • Assembly of active LPL and LIPC lipase complexes
CREM cAMP responsive element modulator

Page 2 out of 10 pages